As the U.S. grapples with the lasting effects of the Covid-19 pandemic, it is important to highlight the ongoing challenges faced by the 7 million immunocompromised Americans. For them, the battle ...
The expanded authorization was based on data from the phase 2/3 BLAZE-1 trial. The Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab plus ...
LOS ANGELES - The U.S. Food and Drug Administration issued an emergency use authorization for Eli Lilly and Company’s monoclonal antibody therapy bamlanivimab to treat mild-to-moderate cases of ...
The pause affects Sotrovimab from GlaxoSmithKline. The federal government is sharply pulling back on one of the monoclonal antibody treatments authorized for COVID-19, pausing its use across eight ...
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking ...
New data has shown the benefits of adding a CD38 monoclonal antibody onto the standard 3-drug regimen for patients with newly diagnosed, transplant-eligible multiple myeloma (MM). For patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results